menu
    • menu
    [{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"M1 Pram P037","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adocia \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Adocia","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Bc Lispram","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Adocia \/ Adocia","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Adocia"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adocia \/ Adocia","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Adocia"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adocia \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Tonghua Dongbao Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Adocia

    Menu

    Adocia

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Tonghua Dongbao Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and HumalogÂÂ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 13, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Tonghua Dongbao Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Tonghua Dongbao Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 13, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Tonghua Dongbao Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Tonghua Dongbao Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneo...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 13, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Tonghua Dongbao Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : Tonghua Dongbao Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase...

                            Details : The primary objective of Phase 3 program is to demonstrate non-inferiority of BC Lispro on HbA1c reduction from baseline vs. Humalog. BioChaperone® Lispro (BC Lispro) is ultra-rapid prandial insulin containing insulin lispro and Adocia’s proprietary t...

                            Product Name : BioChaperone Lispro

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 14, 2021

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : Tonghua Dongbao Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes

                            Details : The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog®, Eli Lilly) in regard to glycemic control and body weight reduction.

                            Product Name : BC LisPram

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 03, 2021

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bc Lispram

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : Michael Tsoukas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of BC LisPram

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            July 22, 2021

                            Lead Product(s) : Bc Lispram

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : Michael Tsoukas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro,Pramlintide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

                            Details : Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.

                            Product Name : BC LisPram

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            June 29, 2021

                            Lead Product(s) : Insulin Lispro,Pramlintide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramlintide,Exenatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinat...

                            Details : Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide-both combinations demonstrated promising effects in obesity treatment.

                            Product Name : PramExe

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            May 26, 2021

                            Lead Product(s) : Pramlintide,Exenatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : M1 Pram P037

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 25, 2021

                            Lead Product(s) : M1 Pram P037

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adocia

                            France arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            August 06, 2020

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth